



Please type a plus sign (+) inside this box.

MAR. 06 2000

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/P

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/584,669
Filing Date	June 1, 2000
First Named Inventor	Edward M. SELLERS, et al.
Group Art Unit	1654
Examiner Name	Michael V. MELLER
Attorney Docket Number	62805.000020

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P1	MAYS, et al., "Methoxsalen is a Potent Inhibitor of the Metabolism of Caffeine in Humans," <i>Clin. Pharmacol. Ther.</i> , 42(6):621-626 (1987).	
	P2	MAENPAA, et al., "Metabolic Interactions of Methoxsalen and Coumarin in Humans and Mice," <i>Biochem. Pharmacol.</i> , 48(7):1363-1369 (1994).	
	P3	BENOWITZ, N.L., ET AL., "Deficient C-Oxidation of Nicotine," <i>Clinical Pharmacology and Therapeutics</i> , 57(5):590-594 (1995) (Abstract).	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.